^
Association details:
Biomarker:ATM mutation
Cancer:Gastroesophageal Junction Adenocarcinoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The mutational pattern of homologous recombination (HR) related genes and its relevance to response to immunotherapy in gastric cancer.

Published date:
05/13/2020
Excerpt:
Fifty-one of 484 (10.54%) patients had at least one somatic mutation in HR-gene, ATM (16/484, 3.31%), ATRX (14/484, 2.89%), and ATR (13/484, 2.69%) were among the top mutated HR-gene...In MSK-GC cohort, including a total of 49 patients who had stomach adenocarcinoma (STAD) or gastroesophageal junction adenocarcinoma (GEJ) and treated with ICIs, HR-mut GC (n = 12) had a significantly better OS than HR-wt GC (n = 37) (log-rank test, P = 0.034).
DOI:
10.1200/JCO.2020.38.15_suppl.e16579